BLI:NSD-Berkeley Lights, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 73.22

Change

-6.73 (-8.42)%

Market Cap

USD 5.15B

Volume

1.87M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Berkeley Lights, Inc., a digital cell biology company that focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. It offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. The company was incorporated in 2011 and is based in Emeryville, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-3.67 (-1.52%)

USD62.75B 23.65 18.31
REGN Regeneron Pharmaceuticals, Inc

-4.10 (-0.75%)

USD58.50B 20.09 15.20
MRNA Moderna, Inc

+4.93 (+3.35%)

USD58.17B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+0.43 (+0.27%)

USD35.28B 37.44 34.58
BGNE BeiGene, Ltd

-18.57 (-4.93%)

USD34.32B N/A N/A
SGEN Seagen Inc

-7.48 (-4.15%)

USD32.24B 68.02 69.56
RPRX Royalty Pharma plc

+1.32 (+2.56%)

USD32.20B 22.60 11.74
GMAB Genmab A/S

-0.64 (-1.50%)

USD28.09B 26.59 3.19
BNTX BioNTech SE

-4.32 (-3.91%)

USD26.63B -99,999.99 N/A
INCY Incyte Corporation

-1.11 (-1.10%)

USD22.01B 47.64 35.20

ETFs Containing BLI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.11% 2% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.11% 2% F 2% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 5.15B 91% A- 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 92% A- 95% A
Price/Book Ratio 20.81 10% F 8% F
Price / Cash Flow Ratio -488.59 99% A+ 98% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -15.03% 83% B 31% F
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 16.78% 51% F 68% D+
Technical Ratios  
Short Ratio 4.35 40% F 30% F
Short Percent 6.04% 53% F 34% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector